PLUR Fundamental Analysis - PLURI INC

Fundamental Rating

Overall PLUR gets a fundamental rating of 2 out of 10. We evaluated PLUR against 531 industry peers in the Biotechnology industry. PLUR has a bad profitability rating. Also its financial health evaluation is rather negative. PLUR shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PLUR has reported negative net income.

In the past year PLUR has reported a negative cash flow from operations.

In the past 5 years PLUR always reported negative net income.

In the past 5 years PLUR always reported negative operating cash flow.

1.2 Ratios

PLUR has a Return On Assets of -66.97%. This is in the lower half of the industry: PLUR underperforms 61.21% of its industry peers.

		Industry Rank	Sector Rank
ROA	-66.97%
ROE	N/A
ROIC	N/A

ROA(3y)-56.03%

ROA(5y)-56.44%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 42.91%, PLUR is in the better half of the industry, outperforming 74.20% of the companies in the same industry.

PLUR's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for PLUR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	42.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-13.31%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PLUR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, PLUR has more shares outstanding

The number of shares outstanding for PLUR has been increased compared to 5 years ago.

Compared to 1 year ago, PLUR has a worse debt to assets ratio.

2.2 Solvency

PLUR has an Altman-Z score of -21.07. This is a bad value and indicates that PLUR is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of PLUR (-21.07) is worse than 85.31% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-21.07

ROIC/WACCN/A

WACC6.8%

2.3 Liquidity

PLUR has a Current Ratio of 0.53. This is a bad value and indicates that PLUR is not financially healthy enough and could expect problems in meeting its short term obligations.

PLUR's Current ratio of 0.53 is on the low side compared to the rest of the industry. PLUR is outperformed by 91.90% of its industry peers.

PLUR has a Quick Ratio of 0.53. This is a bad value and indicates that PLUR is not financially healthy enough and could expect problems in meeting its short term obligations.

PLUR has a worse Quick ratio (0.53) than 91.90% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.53
Quick Ratio	0.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.34% over the past year.

Looking at the last year, PLUR shows a very strong growth in Revenue. The Revenue has grown by 121.74%.

Measured over the past years, PLUR shows a very strong growth in Revenue. The Revenue has been growing by 125.33% on average per year.

EPS 1Y (TTM)24.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.64%

Revenue 1Y (TTM)121.74%

Revenue growth 3Y78.73%

Revenue growth 5Y125.33%

Sales Q2Q%-3.07%

3.2 Future

Based on estimates for the next years, PLUR will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.56% on average per year.

Based on estimates for the next years, PLUR will show a very strong growth in Revenue. The Revenue will grow by 153.63% on average per year.

EPS Next Y12.2%

EPS Next 2Y17.56%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year63.28%

Revenue Next 2Y153.63%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PLUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLUR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PLUR's earnings are expected to grow with 17.56% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.56%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PLUR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PLURI INC

NASDAQ:PLUR (12/11/2025, 8:01:43 PM)

Premarket: 3.02 -0.07 (-2.27%)

3.09

-0.45 (-12.71%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2025-11-12/amc

Earnings (Next)02-09 2026-02-09

Inst Owners14.91%

Inst Owner Change-32.36%

Ins Owners9.79%

Ins Owner Change4.37%

Market Cap28.58M

Revenue(TTM)1.33M

Net Income(TTM)-22.55M

Analysts82.86

Price Target12.24 (296.12%)

Short Float %0.76%

Short Ratio1.66

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-10.21%

Min EPS beat(2)-34.3%

Max EPS beat(2)13.88%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-26.95%

Min Revenue beat(2)-51.44%

Max Revenue beat(2)-2.45%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-4.45%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-42.97%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	21.56
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-3.1

EYN/A

EPS(NY)-1.94

Fwd EYN/A

FCF(TTM)-2.28

FCFYN/A

OCF(TTM)-2.12

OCFYN/A

SpS0.14

BVpS-1.23

TBVpS-1.86

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-66.97%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	42.91%
FCFM	N/A

ROA(3y)-56.03%

ROA(5y)-56.44%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-13.31%

F-Score3

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	400.53%
Cap/Sales	115.08%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.53
Quick Ratio	0.53
Altman-Z	-21.07

F-Score3

WACC6.8%

ROIC/WACCN/A

Cap/Depr(3y)237.36%

Cap/Depr(5y)153.18%

Cap/Sales(3y)103.83%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)24.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.64%

EPS Next Y12.2%

EPS Next 2Y17.56%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)121.74%

Revenue growth 3Y78.73%

Revenue growth 5Y125.33%

Sales Q2Q%-3.07%

Revenue Next Year63.28%

Revenue Next 2Y153.63%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-6.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y1.38%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y7.25%

OCF growth 3YN/A

OCF growth 5YN/A

PLURI INC / PLUR FAQ

Can you provide the ChartMill fundamental rating for PLURI INC?

ChartMill assigns a fundamental rating of 2 / 10 to PLUR.

What is the valuation status of PLURI INC (PLUR) stock?

ChartMill assigns a valuation rating of 0 / 10 to PLURI INC (PLUR). This can be considered as Overvalued.

What is the profitability of PLUR stock?

PLURI INC (PLUR) has a profitability rating of 1 / 10.

How financially healthy is PLURI INC?

The financial health rating of PLURI INC (PLUR) is 0 / 10.

PLURI INC (PLUR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PLURI INC / PLUR FAQ

Can you provide the ChartMill fundamental rating for PLURI INC?

What is the valuation status of PLURI INC (PLUR) stock?

What is the profitability of PLUR stock?

How financially healthy is PLURI INC?